Ian McCaffery

4.0k total citations
45 papers, 1.8k citations indexed

About

Ian McCaffery is a scholar working on Oncology, Molecular Biology and Physiology. According to data from OpenAlex, Ian McCaffery has authored 45 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 15 papers in Molecular Biology and 10 papers in Physiology. Recurrent topics in Ian McCaffery's work include Adenosine and Purinergic Signaling (10 papers), Erythropoietin and Anemia Treatment (7 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Ian McCaffery is often cited by papers focused on Adenosine and Purinergic Signaling (10 papers), Erythropoietin and Anemia Treatment (7 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Ian McCaffery collaborates with scholars based in United States, United Kingdom and Australia. Ian McCaffery's co-authors include Min Zhu, Hongjie Deng, C. Glenn Begley, Susan Swift, Angus M. Sinclair, Anthony W. Tolcher, Leigh Busse, Elwyn Loh, Richard A. Miller and Jennifer Gansert and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ian McCaffery

43 papers receiving 1.8k citations

Peers

Countries citing papers authored by Ian McCaffery

Since Specialization

Citations

This map shows the geographic impact of Ian McCaffery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian McCaffery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian McCaffery more than expected).

Fields of papers citing papers by Ian McCaffery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian McCaffery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian McCaffery. The network helps show where Ian McCaffery may publish in the future.

Co-authorship network of co-authors of Ian McCaffery

This figure shows the co-authorship network connecting the top 25 collaborators of Ian McCaffery. A scholar is included among the top collaborators of Ian McCaffery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian McCaffery. Ian McCaffery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models 2018 ·Cancer Immunology Research ·Stephen B. Willingham, Po Y. Ho, Andrew Hotson, Craig Hill, Emily Piccione, Jessica Hsieh, Liang Liu, Joseph J. Buggy, Ian McCaffery, Richard A. Miller	162
2	Abstract 5593: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies 2017 ·Cancer Research ·Stephen B. Willingham, Andrew Hotson, Po Y. Ho, (unknown), Walter Kim, Erik Yusko, Sharon Benzeno, Ginna G. Laport, Richard A. Miller, Ian McCaffery	1
3	Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1 2016 ·Annals of Oncology ·Stephen B. Willingham, Po Y. Ho, Robert D. Leone, (unknown), Jonathan D. Powell, Ian McCaffery, Richard A. Miller	2
4	Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma 2016 ·JAMA Oncology ·Manish A. Shah, Yung‐Jue Bang, Florian Lordick, María Alsina, Meng Chen, Stephen P. Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S. Shames, See Phan, David Cunningham	209
5	Biomarker and clinical activity of CPI-444, a novel small molecule inhibitor of A2A receptor (A2AR), in a Ph1b study in advanced cancers 2016 ·Annals of Oncology ·Ian McCaffery, Ginna G. Laport, Andrew Hotson, Stephen B. Willingham, Amita Patnaik, M. Beeram, Rebecca L. Miller	6
6	Functional EpoR Pathway Utilization Is Not Detected in Primary Tumor Cells Isolated from Human Breast, Non-Small Cell Lung, Colorectal, and Ovarian Tumor Tissues 2015 ·PLoS ONE ·Scott D. Patterson, John M. Rossi, (unknown), (unknown), C. Glenn Begley, Leigh Busse, Steve Elliott, Ian McCaffery	14
7	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer 2014 ·Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero	92
8	Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor 2013 ·Clinical Cancer Research ·Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki, Sunita Badola, Hedy L. Kindler, Charles S. Fuchs, Elwyn Loh, Scott D. Patterson, Li Chen, Jennifer Gansert	54
9	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer 2013 ·Annals of Oncology ·Allen Lee Cohn, Josep Tabernero, Joan Maurel, Elżbieta Nowara, Javier Sastre, Benjamin Chuah, М. В. Копп, Dina Sakaeva, Edith P. Mitchell, (unknown), Samuel Suzuki, (unknown), Francesco Galimi, Ian McCaffery, Yang Pan, Robert D. Loberg, Susan Cottrell, Su Pin Choo	74
10	Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial 2013 ·The Lancet Oncology ·J.F.R. Robertson, Jean-Marc Ferrero, Hugues Bourgeois, Hagen F. Kennecke, Richard H. De Boer, William Jacot, Jesse McGreivy, Samuel Suzuki, Min Zhu, Ian McCaffery, Elwyn Loh, Jennifer Gansert, Peter A. Kaufman	137
11	Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Lee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang, Hongjie Deng, Jill Gilbert, Devalingam Mahalingam, Ian McCaffery, (unknown), Alain C. Mita, Monica Mita, Marilyn Mulay, (unknown), Min Zhu, John Sarantopoulos	30
12	PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) 2011 ·Annals of Oncology ·Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith Mitchell, Ірина Давиденко, Élena Elez, Kelly S. Oliner, Lisa Chen, Jing Huang, Ian McCaffery, Elwyn Loh, Dominic Smethurst, Eric Van Cutsem	0
13	Lack of expression and function of erythropoietin receptors in the kidney 2011 ·Nephrology Dialysis Transplantation ·Steve Elliott, Leigh Busse, Susan Swift, Ian McCaffery, John M. Rossi, Paul D. Kassner, C. Glenn Begley	31
14	Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc) 2010 ·Annals of Oncology ·Paul Lorigan, J.C. Soria, Joan Stephenson, (unknown), R. Gervais, (unknown), Ian McCaffery, (unknown), Jesse McGreivy, Bonnie S. Glisson	6
15	Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor 2010 ·The Journal of Clinical Pharmacology ·John P. Gibbs, Maurice G. Emery, Ian McCaffery, Blair H. Smith, Megan Gibbs, Anna Akrami, John M. Rossi, (unknown), Marc R. Gastonguay, Edgar Bautista, Minghan Wang, Riccardo Perfetti, (unknown)	33
16	Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors. 2010 ·Journal of Clinical Oncology ·Igor Puzanov, John Sarantopoulos, Jeremy L. Gilbert, Devalingam Mahalingam, Linnea Chap, Hongjie Deng, Min Zhu, Ian McCaffery, Greg Friberg, Lee S. Rosen	4
17	Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells 2009 ·Journal of Immunological Methods ·Steve Elliott, Leigh Busse, Ian McCaffery, (unknown), Angus M. Sinclair, Chris Spahr, Susan Swift, C. Glenn Begley	56
18	Determination of prednisolone in human adipose tissue incubation medium using LC–MS/MS to support the measurement of 11β-hydroxysteroid dehydrogenase activity☆ 2008 ·Journal of Chromatography B ·(unknown), Mark J. Rose, Ian McCaffery, (unknown), (unknown), Clarence Hale, Maurice G. Emery, Christopher James	6
19	Identification of novel elements which regulate the cell-type specificity of Dictyostelium 7E gene expression 2001 ·Differentiation ·(unknown), Bryn Stevens, Ian McCaffery, B.D. Hames	3
20	Transcription of theDictyostelium glycogen phosphorylase-2 gene is induced by three large promoter domains 1998 ·Developmental Genetics ·Reyna Favis, Ian McCaffery, Gretchen Ehrenkaufer, Charles L. Rutherford	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact